within Pharmacolibrary.Drugs.ATC.A;

model A10BD04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 4e-06,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BD04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Glimepiride and rosiglitazone is a fixed-dose combination of an oral sulfonylurea (glimepiride), which stimulates insulin secretion from pancreatic beta cells, and a thiazolidinedione (rosiglitazone), which improves insulin sensitivity in peripheral tissues. The combination is used for the management of type 2 diabetes mellitus in adults. The combination is approved for use in several countries, although rosiglitazone's approval status may vary due to cardiovascular safety concerns.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for healthy adult subjects; individual PK studies generally report on monotherapy, as no published population PK model for the fixed-dose combination was identified.</p><h4>References</h4><ol><li><p>Kirchheiner, J, et al., &amp; Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. <i>Clinical pharmacokinetics</i> 44(12) 1209–1225. DOI:<a href=\"https://doi.org/10.2165/00003088-200544120-00002\">10.2165/00003088-200544120-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16372821/\">https://pubmed.ncbi.nlm.nih.gov/16372821</a></p></li><li><p>Raptis, SA, &amp; Dimitriadis, GD (2001). Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. <i>Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association</i> 109 Suppl 2 S265–S287. DOI:<a href=\"https://doi.org/10.1055/s-2001-18588\">10.1055/s-2001-18588</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11460577/\">https://pubmed.ncbi.nlm.nih.gov/11460577</a></p></li><li><p>Klatt, S, et al., &amp; König, J (2013). The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 112(4) 244–250. DOI:<a href=\"https://doi.org/10.1111/bcpt.12031\">10.1111/bcpt.12031</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23121773/\">https://pubmed.ncbi.nlm.nih.gov/23121773</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BD04;
